About Avadel Pharmaceuticals plc
https://www.avadel.comAvadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy.
CEO
Gregory J. Divis Jr.
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 103
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Wells Fargo
Equal Weight
Leerink Partners
Market Perform
UBS
Neutral
HC Wainwright & Co.
Neutral
Jefferies
Hold
Needham
Hold
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
JANUS HENDERSON GROUP PLC
Shares:7.43M
Value:$159.74M
BLACKROCK, INC.
Shares:6.97M
Value:$149.93M
VANGUARD GROUP INC
Shares:5.61M
Value:$120.54M
Summary
Showing Top 3 of 210
About Avadel Pharmaceuticals plc
https://www.avadel.comAvadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $77.47M ▲ | $78.53M ▲ | $20K ▼ | 0.03% ▼ | $0 ▼ | $3.58M ▼ |
| Q2-2025 | $68.13M ▲ | $52.88M ▲ | $9.66M ▲ | 14.19% ▲ | $0.1 ▲ | $9.92M ▲ |
| Q1-2025 | $52.51M ▲ | $49.94M ▲ | $-4.92M ▲ | -9.37% ▲ | $-0.05 | $-1.78M ▼ |
| Q4-2024 | $50.41M ▲ | $48.9M ▲ | $-5.04M ▼ | -10% ▼ | $-0.05 ▼ | $-1.59M ▼ |
| Q3-2024 | $50.02M | $44.2M | $-2.63M | -5.25% | $-0.03 | $1.32M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $91.58M ▲ | $199.45M ▲ | $101.22M ▲ | $98.22M ▲ |
| Q2-2025 | $81.55M ▲ | $187.16M ▲ | $96.45M ▲ | $90.71M ▲ |
| Q1-2025 | $66.48M ▼ | $167.95M ▲ | $93.88M ▲ | $74.07M ▲ |
| Q4-2024 | $73.78M ▲ | $164.24M ▲ | $90.39M ▲ | $73.85M ▼ |
| Q3-2024 | $65.81M | $158.25M | $83.59M | $74.66M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $20K ▼ | $23.26M ▲ | $-8.79M ▼ | $2.63M ▲ | $16.41M ▲ | $23.25M ▲ |
| Q2-2025 | $9.66M ▲ | $12.7M ▲ | $-8.25M ▼ | $982K ▲ | $7.03M ▲ | $12.52M ▲ |
| Q1-2025 | $-4.92M ▲ | $-8.23M ▼ | $12.32M ▼ | $690K ▼ | $5M ▼ | $-8.23M ▼ |
| Q4-2024 | $-5.04M ▼ | $7.87M ▲ | $14.91M ▲ | $880K ▼ | $22.79M ▲ | $7.87M ▲ |
| Q3-2024 | $-2.63M | $-6.89M | $4.93M | $1.18M | $-265K | $-6.89M |
Revenue by Products
| Product | Q2-2020 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Reportable Segment | $0 ▲ | $50.00M ▲ | $70.00M ▲ | $80.00M ▲ |
 Akovaz | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Bloxiverz | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Other Products | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Vazculep | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
Revenue by Geography
| Region | Q1-2016 |
|---|---|
 FRANCE | $0 ▲ |
 IRELAND | $0 ▲ |
 UNITED STATES | $40.00M ▲ |
CEO
Gregory J. Divis Jr.
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 103
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Wells Fargo
Equal Weight
Leerink Partners
Market Perform
UBS
Neutral
HC Wainwright & Co.
Neutral
Jefferies
Hold
Needham
Hold
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
JANUS HENDERSON GROUP PLC
Shares:7.43M
Value:$159.74M
BLACKROCK, INC.
Shares:6.97M
Value:$149.93M
VANGUARD GROUP INC
Shares:5.61M
Value:$120.54M
Summary
Showing Top 3 of 210